Amneal Pharmaceuticals, Inc. (AMRX) announced Wednesday it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration for lisdexamfetamine dimesylate capsules, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg.